TLE3

Across TCGA pan-cancer cohorts, TLE3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TLE3 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TLE3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TLE3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where TLE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.278	0.486	.010	14	view →
LSCC	OS	Tertile	All	0.910	0.748	.014	6	view →
GBM	OS	Median	All	0.749	0.960	.009	3	view →
UCEC	OS	Quartile	All	1.000	0.871	.028	2	view →
HNSC	DFS	Median	IV	0.575	0.763	.037	2	view →
CCRCC	DFS	Tertile	II,III,IV	0.784	0.260	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TLE3–PDAC (DFS)

Open the PDAC breakdown →